180 related articles for article (PubMed ID: 38019508)
1. Semaglutide Improved Cardiovascular Health in People Without Diabetes.
Harris E
JAMA; 2023 Dec; 330(23):2241-2242. PubMed ID: 38019508
[No Abstract] [Full Text] [Related]
2. Highlights From AHA 2023-New Risk Calculator, Semaglutide and CVD, and More.
Abbasi J
JAMA; 2023 Dec; 330(23):2237-2240. PubMed ID: 37991804
[TBL] [Abstract][Full Text] [Related]
3. Diabetes: Cardiovascular benefits of semaglutide.
Lim GB
Nat Rev Cardiol; 2016 Dec; 13(12):697. PubMed ID: 27708277
[No Abstract] [Full Text] [Related]
4. Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes.
Basolo A; Fierabracci P; Salvetti G; Santini F
J Endocrinol Invest; 2024 May; 47(5):1047-1049. PubMed ID: 38157134
[No Abstract] [Full Text] [Related]
5. GLP-1 receptor agonists and cardiovascular outcome trials: An update.
Andrikou E; Tsioufis C; Andrikou I; Leontsinis I; Tousoulis D; Papanas N
Hellenic J Cardiol; 2019; 60(6):347-351. PubMed ID: 30528435
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.
Nauck MA; Quast DR
Front Endocrinol (Lausanne); 2021; 12():645566. PubMed ID: 33854484
[TBL] [Abstract][Full Text] [Related]
7. Response to "Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes".
Cheema MRS; Kumar S
Acta Diabetol; 2023 May; 60(5):715-716. PubMed ID: 36899150
[No Abstract] [Full Text] [Related]
8. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
Doggrell SA
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
Tan X; Cao X; Zhou M; Zou P; Hu J
Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
[TBL] [Abstract][Full Text] [Related]
10. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.
Newsome P; Francque S; Harrison S; Ratziu V; Van Gaal L; Calanna S; Hansen M; Linder M; Sanyal A
Aliment Pharmacol Ther; 2019 Jul; 50(2):193-203. PubMed ID: 31246368
[TBL] [Abstract][Full Text] [Related]
11. Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?
Doggrell SA
Expert Opin Biol Ther; 2020 May; 20(5):489-492. PubMed ID: 32005073
[No Abstract] [Full Text] [Related]
12. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
Bain SC; Mosenzon O; Arechavaleta R; Bogdański P; Comlekci A; Consoli A; Deerochanawong C; Dungan K; Faingold MC; Farkouh ME; Franco DR; Gram J; Guja C; Joshi P; Malek R; Merino-Torres JF; Nauck MA; Pedersen SD; Sheu WH; Silver RJ; Tack CJ; Tandon N; Jeppesen OK; Strange M; Thomsen M; Husain M
Diabetes Obes Metab; 2019 Mar; 21(3):499-508. PubMed ID: 30284349
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Goldman JD
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
[TBL] [Abstract][Full Text] [Related]
14. [Advantages of glucagon-like peptide-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus: A review].
Demidova TY; Titova VV; Izmaylova MY
Ter Arkh; 2023 Nov; 95(10):876-880. PubMed ID: 38159021
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA; Quast DR; Wefers J; Meier JJ
Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
17. Semaglutide reduces the absolute risk of major cardiovascular events by 1.5.
Phizackerley D
BMJ; 2024 Jan; 384():q53. PubMed ID: 38224977
[No Abstract] [Full Text] [Related]
18. Safety of Semaglutide.
Smits MM; Van Raalte DH
Front Endocrinol (Lausanne); 2021; 12():645563. PubMed ID: 34305810
[TBL] [Abstract][Full Text] [Related]
19. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.
Peterson SC; Barry AR
Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990
[TBL] [Abstract][Full Text] [Related]
20. [Semaglutide for the Management of type 2 Diabetes: Clinical Evidence, Cardioprotective Effects, and Guidelines].
Kobalava ZD; Kokhan EV
Kardiologiia; 2020 Oct; 60(9):122-133. PubMed ID: 33131483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]